the editorial board of Genetic Testing and Biomarkers, Biopreservation and Biobanking, and the Google Health and Rosalind Franklin Society Advisory Boards. Ms. Terry is the chair of the Coalition for Genetic Fairness that was instrumental in the passage of the Genetic Information Nondiscrimination Act and is co-chair of the Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health. In 2005, she received an honorary doctorate from Iona College for her work in community engagement; the first Patient Service Award from the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy in 2007; the Research!America Distinguished Organization Advocacy Award in 2009; and the Clinical Research Forum and Foundation’s Annual Award for Leadership in Public Advocacy in 2011. She is also an Ashoka Fellow. Ms. Terry is committed to personal transformation as a catalyst for the system change needed to improve health and wellness.
Mark Trusheim is a visiting scientist and executive in residence at the Massachusetts Institute of Technology (MIT) Sloan School of Management. He has been a special government employee for the FDA’s Office of the Commissioner and is the founder and president of Co-Bio Consulting, LLC. He holds degrees in chemistry from Stanford University and management from MIT. Mr. Trusheim’s research focuses on regional innovation industry economic clusters and modeling the introduction of new innovations in health care, such as stratified medicines, to inform public policy, corporate strategy, and product development programs. He is a former member of the Massachusetts Biotechnology Council’s board of directors, which helps its more than 500 members succeed in the state. In 2004 he further served as the interim president of the council, leading its successful legislative agenda, its expansion of MassBioEd education programs, and its continued membership growth. Co-Bio Consulting focuses on biotechnology public policy, corporate development, and financing. Co-Bio Consulting helps life sciences firms secure partners and rapidly move their research to market by connecting strategy formation to action. The firm also helps facilitate academic, government, and industry consortia to grow life sciences economic clusters. Clients include established biopharma firms, start-up biotechs, universities, and government agencies. As an entrepreneur, Mr. Trusheim founded and was the first president and chief executive officer of Cantata Laboratories. Cantata marketed clinical diagnostics and pharmaceutical biomarker services based on its biochemical profiling platform. Prior to Cantata, Mr. Trusheim worked at Monsanto/Pharmacia, culminating his career there as co-president and chief operating officer of Cereon Genomics, LLC. Located in Cambridge, Massachusetts, Cereon was created in 1997 by Monsanto as part of a $500 million collaboration with Millennium Pharmaceuticals. Prior to his position at Cereon, Mr. Trusheim